Clinical Efficacy of Sacubitril Valsartan Combined with Pitavastatin in the Treatment of Coronary Heart Disease Complicated with Heart Failure
[Objective]To investigate the clinical efficacy of sacubitril valsartan combined with pitavastatin in the treat-ment of coronary heart disease(CHD)with heart failure(HF).[Methods]A retrospective analysis was conducted on the clinical data of 82 patients with CHD combined with HF admitted to our hospital from February 2020 to February 2022.According to the treatment method,they were divided into the control group(treated with pitavastatin in addition to con-ventional treatment)and the observation group(treated with sacubitril in addition to the control group),with 41 patients in each group.Two groups were compared in terms of clinical efficacy,cardiac function indicators[left ventricular ejection fraction(LVEF),left ventricular end diastolic diameter(LVEDD),left ventricular end systolic diameter(LVESD)],6-minute walk test(6MWT)distance,and quality of life[Minnesota Heart Failure Quality of Life Scale(LHFQ score)],and the incidence of adverse reactions during treatment was statistically analyzed.[Results]The total effective rate of the observation group was higher than that of the control group,and the difference was statistically significant(P＜0.05).Af-ter treatment,LVEF in both groups was higher than before treatment,while LVEDD and LVESD were lower than before treatment.The differences between the observation group and the control group were statistically significant(P＜0.05).After treatment,the distance between the two groups of 6MWT distarce was greater than before treatment,and the LHFQ score was lower than before treatment.Moreover,the difference between the observation group and the control group was statistically significant(P＜0.05).There was no statistically significant difference in the incidence of adverse reactions be-tween the two groups(P＞0.05).[Conclusion]The combination of sacubitril valsartan and pitavastatin has a good thera-peutic effect on CHD complicated with HF,significantly improving patients'cardiac function,enhancing their quality of life,and has high safety.
万方数据
维普
